Healthcare / Drug Manufacturers - Specialty & GenericBSE
$46.80
-2.84 (-5.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-318.1M · quality 60.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.3B
P/E
24.2x
↑EV/EBITDA
10.5x
↓ROE
8.9%
↑Gross Margin
20.1%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+71.3%
FCF CAGR
—
FCF margin
-1.6%
FCF / Net income
-0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.55B · net income $109.3M · FCF $-106.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.55B | $6.55B | $3.86B | $2.33B | $1.30B |
| Net Income | $109.3M | $109.3M | $4.6M | $27.6M | $45.1M |
| EBITDA | $211.1M | $211.1M | $40.2M | $71.5M | $88.7M |
| EPS | — | — | 0.11 | 0.78 | 1.42 |
| Gross Margin | 20.1% | 20.1% | 20.5% | 24.8% | 24.3% |
| Operating Margin | 2.6% | 2.6% | 0.3% | 1.8% | 4.6% |
| Net Margin | 1.7% | 1.7% | 0.1% | 1.2% | 3.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | — | 0.01 | 0.07 |
| Current Ratio | 1.34 | 1.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-106.7M | $-106.7M | $-318.1M | $-323.3M | $-104.5M |
| Returns | |||||
| ROE | 8.9% | 8.9% | 0.5% | 4.8% | 20.2% |
| Valuation | |||||
| P/E | 24.25 | 24.25 | 356.48 | — | — |
| EV/EBITDA | 10.50 | 10.50 | 40.22 | — | — |
| P/B | 1.87 | 1.87 | 1.80 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 69.5% | 69.5% | 65.5% | 79.1% | — |
| EPS Growth | — | — | -86.2% | -45.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.11 → n/d
Residual
+8.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.